Cargando…

Autologous protein solution: a promising solution for osteoarthritis?

Osteoarthritis (OA) is a global health issue with myriad pathophysiological factors and is one of the most common causes of chronic disability in adults due to pain and altered joint function. The end stage of OA develops from a destructive inflammatory cycle, driven by the pro-inflammatory cytokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Bin Abd Razak, Hamid Rahmatullah, Chew, Daniel, Kazezian, Zepur, Bull, Anthony M.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: British Editorial Society of Bone and Joint Surgery 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489471/
https://www.ncbi.nlm.nih.gov/pubmed/34667642
http://dx.doi.org/10.1302/2058-5241.6.200040
_version_ 1784578344072773632
author Bin Abd Razak, Hamid Rahmatullah
Chew, Daniel
Kazezian, Zepur
Bull, Anthony M.J.
author_facet Bin Abd Razak, Hamid Rahmatullah
Chew, Daniel
Kazezian, Zepur
Bull, Anthony M.J.
author_sort Bin Abd Razak, Hamid Rahmatullah
collection PubMed
description Osteoarthritis (OA) is a global health issue with myriad pathophysiological factors and is one of the most common causes of chronic disability in adults due to pain and altered joint function. The end stage of OA develops from a destructive inflammatory cycle, driven by the pro-inflammatory cytokines interleukin-1β (IL-1β) and tumour necrosis factor alpha (TNFα). Owing to the less predictable results of total knee arthroplasty (TKA) in younger patients presenting with knee OA, there has been a surge in research evaluating less invasive biological treatment options, one of which is autologous protein solution (APS). APS is an autologous blood derivative obtained by using a proprietary device, made of APS separator, which isolates white blood cells (WBCs) and platelets in a small volume of plasma, and APS concentrator, which further concentrates platelets, WBCs and plasma proteins, resulting in a concentrated solution with high levels of growth factors including the anti-inflammatory mediators against IL-1β and TNFα. A single intraarticular injection of APS appears to be a promising solution for treatment of early-stage OA from current evidence, the majority of which comes from preclinical studies. More clinical studies are needed before APS can be widely accepted as a treatment modality for OA. Cite this article: EFORT Open Rev 2021;6:716-726. DOI: 10.1302/2058-5241.6.200040
format Online
Article
Text
id pubmed-8489471
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher British Editorial Society of Bone and Joint Surgery
record_format MEDLINE/PubMed
spelling pubmed-84894712021-10-18 Autologous protein solution: a promising solution for osteoarthritis? Bin Abd Razak, Hamid Rahmatullah Chew, Daniel Kazezian, Zepur Bull, Anthony M.J. EFORT Open Rev General Orthopaedics Osteoarthritis (OA) is a global health issue with myriad pathophysiological factors and is one of the most common causes of chronic disability in adults due to pain and altered joint function. The end stage of OA develops from a destructive inflammatory cycle, driven by the pro-inflammatory cytokines interleukin-1β (IL-1β) and tumour necrosis factor alpha (TNFα). Owing to the less predictable results of total knee arthroplasty (TKA) in younger patients presenting with knee OA, there has been a surge in research evaluating less invasive biological treatment options, one of which is autologous protein solution (APS). APS is an autologous blood derivative obtained by using a proprietary device, made of APS separator, which isolates white blood cells (WBCs) and platelets in a small volume of plasma, and APS concentrator, which further concentrates platelets, WBCs and plasma proteins, resulting in a concentrated solution with high levels of growth factors including the anti-inflammatory mediators against IL-1β and TNFα. A single intraarticular injection of APS appears to be a promising solution for treatment of early-stage OA from current evidence, the majority of which comes from preclinical studies. More clinical studies are needed before APS can be widely accepted as a treatment modality for OA. Cite this article: EFORT Open Rev 2021;6:716-726. DOI: 10.1302/2058-5241.6.200040 British Editorial Society of Bone and Joint Surgery 2021-09-14 /pmc/articles/PMC8489471/ /pubmed/34667642 http://dx.doi.org/10.1302/2058-5241.6.200040 Text en © 2021 The author(s) https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC BY-NC 4.0) licence (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.
spellingShingle General Orthopaedics
Bin Abd Razak, Hamid Rahmatullah
Chew, Daniel
Kazezian, Zepur
Bull, Anthony M.J.
Autologous protein solution: a promising solution for osteoarthritis?
title Autologous protein solution: a promising solution for osteoarthritis?
title_full Autologous protein solution: a promising solution for osteoarthritis?
title_fullStr Autologous protein solution: a promising solution for osteoarthritis?
title_full_unstemmed Autologous protein solution: a promising solution for osteoarthritis?
title_short Autologous protein solution: a promising solution for osteoarthritis?
title_sort autologous protein solution: a promising solution for osteoarthritis?
topic General Orthopaedics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489471/
https://www.ncbi.nlm.nih.gov/pubmed/34667642
http://dx.doi.org/10.1302/2058-5241.6.200040
work_keys_str_mv AT binabdrazakhamidrahmatullah autologousproteinsolutionapromisingsolutionforosteoarthritis
AT chewdaniel autologousproteinsolutionapromisingsolutionforosteoarthritis
AT kazezianzepur autologousproteinsolutionapromisingsolutionforosteoarthritis
AT bullanthonymj autologousproteinsolutionapromisingsolutionforosteoarthritis